Effects of the balance between type 1 and type 2 T helper cells on ovarian cancer

Hao, Chenjun; Li, J.; Liu, P.; Li, X.L.; Hu, Yu-hong; Sun, Jing; Wei, Yanli

doi:10.4238/gmr.15027936

Cited by 15 publications

(13 citation statements)

References 14 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…[ 48 ] It is suggested that Th1 adaptive immunity is essential for cancer inhibition and better outcomes. [ 49 , 50 , 51 ] These may be because of the small sample size of this study. In our further studies, we will enlarge our sample size and investigate the function of Th1 cells and IFN-γ.…”

Section: Discussionmentioning

confidence: 94%

Elevated Th22 cells and related cytokines in patients with epithelial ovarian cancer

et al. 2017

View full text Add to dashboard Cite

show abstract

Section: Discussionmentioning

confidence: 94%

Elevated Th22 cells and related cytokines in patients with epithelial ovarian cancer

et al. 2017

View full text Add to dashboard Cite

show abstract

“…13 Such juxtaposing contributions suggest that there is a critical balance between anti-tumor and pro-tumor environments, which may often be tilted in favor of tumor growth and escape from immunological surveillance. 14,15 Previous studies have identified specific immune mediators and pathways in patient sera, ovarian carcinoma ascites and tumor lesions that may hold predictive or prognostic value. 14,[16][17][18][19][20] We hypothesized that a broader evaluation of secreted immune, inflammatory and angiogenic mediator signatures, reflecting the tumor-associated immunological environment, may associate with differential clinical prognoses.…”

Section: Introductionmentioning

confidence: 99%

“…14,15 Previous studies have identified specific immune mediators and pathways in patient sera, ovarian carcinoma ascites and tumor lesions that may hold predictive or prognostic value. 14,[16][17][18][19][20] We hypothesized that a broader evaluation of secreted immune, inflammatory and angiogenic mediator signatures, reflecting the tumor-associated immunological environment, may associate with differential clinical prognoses. In this study, we selected 44 immune, inflammatory and angiogenic mediators known to be involved in immune response to pathogens.…”

Section: Introductionmentioning

confidence: 99%

Immune mediator expression signatures are associated with improved outcome in ovarian carcinoma

et al. 2019

View full text Add to dashboard Cite

Immune and inflammatory cascades may play multiple roles in ovarian cancer. We aimed to identify relationships between expression of immune and inflammatory mediators and patient outcomes. We interrogated differential gene expression of 44 markers and marker combinations (n = 1,978) in 1,656 ovarian carcinoma patient tumors, alongside matched 5-year overall survival (OS) data in silico. Using machine learning methods, we investigated whether genomic expression of these 44 mediators can discriminate between malignant and non-malignant tissues in 839 ovarian cancer and 115 nonmalignant ovary samples. We furthermore assessed inflammation markers in 289 ovarian cancer patients' sera in the Swedish Apolipoprotein MOrtality-related RISk (AMORIS) cohort. Expression of the 44 mediators could discriminate between malignant and non-malignant tissues with at least 96% accuracy. Higher expression of classical Th1, Th2, Th17, anti-parasitic/infection and M1 macrophage mediator signatures were associated with better OS. Contrastingly, inflammatory and angiogenic mediators, CXCL-12, C-reactive protein (CRP) and platelet-derived growth factor subunit A (PDGFA) were negatively associated with OS. Of the serum inflammatory markers in the AMORIS cohort, women with ovarian cancer who had elevated levels of haptoglobin (≥1.4 g/L) had a higher risk of dying from ovarian cancer compared to those with haptoglobin levels <1.4 g/L (HR = 2.09, 95% CI:1.38-3.16). Our findings indicate that elevated "classical" immune mediators, associated with response to pathogen antigen challenge, may confer immunological advantage in ovarian cancer, while inflammatory markers appear to have negative prognostic value. These highlight associations between immune protection, inflammation and clinical outcomes, and offer opportunities for patient stratification based on secretome markers.

show abstract

“…These cytokines can be expressed in small amounts in the normal ovaries as well [8]. Previous assessments of protein concentration of cytokines in serum and ascites of EOC patients and in supernatants of EOC cell lines have shown that there is a shift towards immunoinhibitory cytokines [8][9][10][11][12][13]. Additionally, in earlier reports from the nineties, attempts were made to assess mRNA expression for a limited number of individual cytokines in tumor tissue using Northern blot or semi-quantitative RT-PCR [14][15][16][17].…”

Section: Total Rna Extraction and Real-time Quantitative Reverse Tranmentioning

confidence: 99%

Assessment of Cytokine mRNA Expression Profiles in Tumor Microenvironment and Peripheral Blood Mononuclear Cells of Patients with High-grade Serous Carcinoma of the Ovary

Israelsson¹,

Labani‐Motlagh²,

Nagaev³

et al. 2017

J Cancer Sci Ther

View full text Add to dashboard Cite

Objective: Tumor establishment, metastatic spreading and poor survival in ovarian cancer is strongly associated with progressive derangement of the patient's immune system. Accumulating evidence suggests that immune impairment is influenced by the production and presence of cytokines in the tumor microenvironment.Methods: Cytokine mRNA profiles in tumor tissue and peripheral blood mononuclear cells (PBMC) were analyzed in patients with high grade serous carcinoma (HGSC) of the ovary and compared it to patients with benign ovarian conditions and controls with normal ovaries. Cytokine assessment was done by real-time quantitative RT-PCR and specific primers and probes for 12 cytokines-IFN-γ, IL-1β, IL-2, IL-4, IL-6, IL-8, IL-10, IL-15, TNF-α, TNF-β/LTA, TGF-β1, and GM-CSF chosen to distinguish between cytotoxic Th1, humoral Th2, regulatory Th3/Tr1 and inflammatory responses. Results:The cytokine mRNA response in the HGSC patients was significantly up regulated compared to patients with benign ovarian conditions and normal ovary controls confirming the immunogenicity of HGSC and implying immune recognition and reaction locally in the tumor microenvironment and systemically in the peripheral blood.There was an up-regulation of inflammatory and inhibitory cytokine mRNA promoting tumor progression, T-regulatory cell priming and T-regulatory cell-mediated immune suppression. In contrast, there was an inability to mount the crucially important IFN gamma response needed for upregulation of the cytotoxic anti-tumor response in the local microenvironment. In addition, systemic IL-4-mediated Th2 response prevailed in the peripheral blood deviating the systemic defense towards humoral immunity. Conclusions:Taken together, these results suggest local and systemic cytokine cooperation promoting tumor survival, progression and immune escape. Our study confirms and extends previous investigations and contributes to the evaluation of potential cytokine candidates for diagnostic cytokine mRNA profiles and for future therapeutic interventions based on cytokine inhibition.

show abstract

Effects of the balance between type 1 and type 2 T helper cells on ovarian cancer

Cited by 15 publications

References 14 publications

Elevated Th22 cells and related cytokines in patients with epithelial ovarian cancer

Elevated Th22 cells and related cytokines in patients with epithelial ovarian cancer

Immune mediator expression signatures are associated with improved outcome in ovarian carcinoma

Assessment of Cytokine mRNA Expression Profiles in Tumor Microenvironment and Peripheral Blood Mononuclear Cells of Patients with High-grade Serous Carcinoma of the Ovary

Contact Info

Product

Resources

About